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Sphingosine 1-phosphate signallingSphingosine kinase 1 (SK1) is an enzyme that catalyses the phosphorylation of sphingosine to produce the
bioactive lipid sphingosine 1-phosphate (S1P). We demonstrate here that FTY720 (Fingolimod™) and (S)-
FTY720 vinylphosphonate are novel inhibitors of SK1 catalytic activity and induce the proteasomal
degradation of this enzyme in human pulmonary artery smooth muscle cells, MCF-7 breast cancer cells and
androgen-independent LNCaP-AI prostate cancer cells. Proteasomal degradation of SK1 in response to
FTY720 and (S)-FTY720 vinylphosphonate is associated with the down-regulation of the androgen receptor
in LNCaP-AI cells. (S)-FTY720 vinylphosphonate also induces the apoptosis of these cells. These ﬁndings
indicate that SK1 is involved in protecting LNCaP-AI from apoptosis. This protection might be mediated by
so-called ‘inside-out’ signalling by S1P, as LNCaP-AI cells exhibit increased expression of S1P2/3 receptors and
reduced lipid phosphate phosphatase expression (compared with androgen-sensitive LNCaP cells) thereby
potentially increasing the bioavailability of S1P at S1P2/3 receptors.x: +44 0141 552 2562.
-NC-ND license.© 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is produced
by the enzyme sphingosine kinase (SK1 and SK2 isoforms), which
catalyses the phosphorylation of sphingosine to produce S1P [1].
There are three N-terminal variants of SK1. SK1a (GenBank number:
NM_001142601) is a 42 kDa protein, while SK1b (GenBank number:
NM_182965) is a 51 kDa protein identical to SK1a, but with an 86
amino acid N-terminal extension. The third form has amolecularmass
of 44 kDa and is identical to SK1a except for a 14 amino acid N-
terminal extension (termed here SK1a+14, GenBank number:
NM_021972) and migrates with similar mobility as SK1a on SDS-
PAGE. The annotation SK1a used herein therefore includes SK1a and
SK1a+14. S1P has an important role in regulating the growth,
survival and migration of mammalian cells, mediating many of its
effects by binding to a family of ﬁve G-protein coupled receptors
(GPCR) termed S1Pn (where n=1–5) that regulate various effectors,
such as MAP kinase [1].The immunosuppressant FTY720 (Fingolimod™) is a sphingosine
analogue that is taken up by cells and is phosphorylated to FTY720-
phosphate by SK2 [2], which is then released. FTY720-phosphate
binds to four of the ﬁve S1P receptors [3] (S1P2 being the exception)
and elicits polyubiquitination, endocytosis and degradation of S1P1 in
T-lymphocytes [4]. S1P/S1P1 is essential for effective T-lymphocyte
egress, and therefore the FTY720 phosphate-induced down-regula-
tion of S1P1 on T-lymphocytes results in their retention in the lymph
[5]. FTY720 is considered a T-lymphocyte speciﬁc immunosuppres-
sant, and is currently in phase III trials for treatment of multiple
sclerosis.
However, there are many studies that demonstrated that while
FTY720 phosphate induces proliferation of cells, FTY720 induces
apoptosis. For instance, treatment of human breast cancer cells (MCF-
7, MDA-MB-231 and Sk-Br-3 cells) with FTY720 and the FTY720
analogue ISP-I-55 inhibits growth, activates JNK, and transiently
inhibits ERK-1/2 activationwith no effect on p38MAPK inMCF-7 cells.
In contrast, FTY720 phosphate induces growth of these cells [6].
FTY720 also inhibits growth, migration, colony formation and
invasiveness of pancreatic cells (BxPC-3, AsPC-1 and PANC-1) linked
with down-regulation of phosphorylated Akt and Bcl2 and increased
caspase-3 activation [7]. FTY720 also suppresses liver tumour growth,
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levels and enhanced caspase-3 auto-cleavage [8]. FTY720 also induces
apoptosis of androgen-insensitive DU145 prostate cancer cells via a
caspase-3-dependent mechanism [9] and similarly in human renal
cancer cells, resulting in reduced xenograft tumour growth [10].
FTY720 also induces apoptosis of hepatocellular carcinonoma cells
through activation of PKCδ [11] and impairs chemical-induced lung
carcinogenesis and early lung adenoma development by increasing
caspase-3 activation [12]. Multiple myeloma cells [13] and several
bladder cancer cell lines such as T24, UMUC3 and HT1197 also
undergo apoptosis in response to FTY720 via a Bcl2-dependent and
Fas-independentmechanism [14]. FTY720 is also cytotoxic tomultiple
myeloma cell lines and freshly isolated tumour cells from multiple
myeloma patients. This cytotoxicity is mediated by activation of
caspase-8, -9 and -2 and altered BAX cleavage and mitochondrial
potential. There is also marked down-regulation of IL6-stimulated Akt
phosphorylation, STAT3 and ERK-1/2 activation and IGF-I-stimulated
Akt activation and TNFα-stimulated IKB and NFκB phosphorylation.
FTY720 also induces apoptosis of B-cell malignancies and primary B
cells from patients with chronic lymphocytic leukemia (CLL).
However, this is mediated by down-regulation of Mcl-1 and not Bcl-
2, and indeed survival cannot be rescued by enforced expression
of Bcl-2. FTY720 also induces prolonged survival in a xenograft
severe combined immunodeﬁciency (SCID) mouse model of dissem-
inated B-cell lymphoma/leukemia [15]. Taking these ﬁndings togeth-
er, it is clear that FTY720 functions as a bona-ﬁde apoptotic agent.
In this study we have examined whether FTY720 and a novel
analogue, (S)-FTY720 vinylphosphonate regulate SK1 expression in
human pulmonary smooth muscle cells (hPASMC), MCF-7 breast
cancer cells and androgen-independent LNCaP-AI prostate cancer
cells. LNCaP-AI cells have been selected by culturing LNCaP cells in
androgen-deprivation conditions for prolonged periods of time. This
mimics androgen ablation therapy used for the treatment of prostate
cancer [16]. LNCaP-AI cells are not dependent upon androgen for
proliferation as they can grow in hormone-free medium. However,
these cells do express the androgen receptor (AR) and respond to
androgens, being able to express androgen-regulated genes such as
the PSA (Prostatic Speciﬁc Antigen) gene [16]. Moreover, resistance to
chemotherapeutic agents and irradiation of androgen-independent
prostate cancer cells is purported to bemediated by SK1 [17–19]. In this
article, we demonstrate for the ﬁrst time that (S)-FTY720 vinylpho-
sphonate inhibits SK1 activity and induces a novel proteasomal
degradation of this enzyme. This is associated with the induction of
apoptosis and a reduction in androgen receptor expression in androgen-
independent prostate cancer cells.
2. Materials and methods
2.1. Materials
All general biochemicals and anti-actin antibody were from Sigma
(Poole, UK). High glucose Dulbecco's modiﬁed Eagle's medium
(DMEM), RPMI 1640 medium, minimum essential medium (MEM),
European Fetal Calf Serum (EFCS) and penicillin-streptomycin (peni-
cillin G sodium 10,000 units/ml-streptomycin sulphate 10,000 μg/ml)
were from Invitrogen (Paisley, UK). Human pulmonary artery smooth
muscle cells (hPASMC), human smoothmuscle cell growthmediumand
passaging solutions were from TCS Cellworks (Buckingham, UK). Anti-
phosphorylated ERK1/2 and anti-androgen receptor antibodies were
from Santa Cruz (California, USA), anti-ERK2 antibody was from BD
Transduction Biosciences (Oxford, UK), anti-SK1 antibodies were a gift
from A. Huwiler (University of Bern, Switzerland [20]), anti-PARP and
anti-cleaved caspase-3 antibodies were fromCell Signalling Technology
(New England Biolabs (UK) Ltd., Hitchin, UK). MG132 was from Enzo
Life Sciences (Exeter, UK). 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)
thiazole (SKi) was from Merck Biosciences (Nottingham, UK). N,N-Dimethylsphingosine (DMS) was from Avanti (Alabaster, Alabama,
USA). FTY720 was from Cayman (Tallinn, Estonia). (S)-FTY720
vinylphosphonate and FTY720 phosphonates were synthesised accord-
ing to Lu et al. [21]. (S)-FTY720 phosphatewas synthesised according to
Lu and Bittman [22].
2.2. Cell culture
hPASMC were cultured in human smooth muscle cell growth
mediumMCF-7 breast cancer cellswere grown inDMEMsupplemented
with10%EFCS and1%penicillin-streptomycin, 0.4% geneticin and15 μg/
ml insulin. Human prostate cancer LNCaP and LNCaP-AI cell lines
(derived from the parental LNCaP cells by prolonged androgen
depletion) were maintained in RPMI 1640 medium supplemented
with 10% EFCS or 10% delipidated serum, respectively, 1% penicillin-
streptomycin and 1% L-Glutamine. All cells were maintained at 37 °C
with 5% CO2. HEK 293 cells weremaintained inMEMwith 10% EFCS and
1% penicillin-streptomycin. For LNCaP-AI cells, FTY720, (S)-FTY720
vinylphosphonate,MG132 and SKiwere replenished after 24 h. FTY720,
FTY720 phosphate, FTY720 phosphonate, FTY720 (S)-vinylphospho-
nate, SKi andDMSwere dissolved inDMSOand added tomedia at aﬁnal
concentration of DMSO b0.1% (v/v).
2.3. Transfection
HEK 293 cells were transfected with FLAG tagged hSK1 plasmid
construct, using the Lipofectamine™2000 reagent according to the
manufacturer's instruction.
2.4. Preparation of whole cell protein extracts
hPASMC protein lysates were prepared by washing treated cells
(including ﬂoating cells, where appropriate, e.g. for analysis of
apoptosis) with 5 ml of PBS, then resuspending the cell pellets in
whole cell lysis buffer (137 mMNaCl, 2.7 mM KCl, 1 mMMgCl2, 1 mM
CaCl2, 1% v/v NP40, 10% v/v glycerol, 20 mM Tris) (pH 8.0) containing
0.2 mM PMSF, 0.2 mM leupeptin, 0.2 mM aprotinin, 0.5 mM Na3VO4,
100 μM NaF, 10 mM β-glycerophosphate). Samples were passed
through a 23-gauge needle and syringe (× 6) and rotated for 30 min
at 4 °C to allow for efﬁcient lysis. Cell debris was pelleted by
centrifugation at 15,300 rpm for 10 min at 4 °C. The protein content
of the supernatant (whole cell extract) was measured using the Pierce
BCA assay kit (Fisher Scientiﬁc UK, Loughborough). LNCaP-AI cells
were harvested in the same way. For each sample, 10–20 μg of
protein, combined with sample buffer (0.5 M Tris, 2 mM Na4P2O7,
5 mM EDTA, 2% w/v SDS (pH 6.7) containing 5% v/v glycerol, 0.25% w/
v bromophenol blue, 50 mM dithiothreitol) were used for SDS-PAGE
and western blotting. MCF-7 cell lysates were prepared by adding
sample buffer to adherent cells, and the samples were passed through
a 23-gauge needle and syringe (× 6).
2.5. Western blotting
Analysis of proteins by SDS-PAGE and western blotting was
performed as previously described [23] using anti-phosphorylated
ERK1/2, anti-ERK2, anti-PARP, anti-cleaved caspase-3, anti-SK1, anti-
actin and anti-AR antibodies.
2.6. Sphingosine kinase assay
Assays were performed according to Delon et al. [24]. SK1 activity
was measured as the formation of [32P]S1P from sphingosine
and [32P]-γ-ATP using puriﬁed recombinant SK1 (BioMol). Sphingo-
sine (10 μM ﬁnal concentration) was solubilised in 40 μl 5 mM
Triton X-100 (0.313% w/v) and combined with 140 μl assay buffer
(containing 20 mM Tris base (pH 7.4), 1 mM EDTA, 1 mM Na3VO4,
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(v/v) glycerol, 10 μg/ml aprotinin, 10 μg/ml soyabean trypsin inhibitor,
1 mM PMSF, 0.5 mM 4-deoxypyridoxine) and 10 μl of diluted puriﬁed
SK1 (15 ng) or HEK 293 cell lysates containing over-expressed
recombinant SK1. Reactions were started by the addition of [32P]ATP
(4.4×104 cpm/nmole, ﬁnal concentration of ATP, 250 μM) and incu-
bated at 30 °C for 15 min. Reactions were terminated by the addition of
500 μl 1-butanol and the samples mixed thoroughly before phase
separation by the addition of 1 ml 2 M KCl. The lower aqueous phase
was discarded, the upper phase washed twice with 1 ml 2 M KCl and
[32P]S1P therein quantiﬁed by scintillation counting.2.7. Polymerase Chain Reaction (PCR)
PCR was performed to identify mRNA transcripts. The primers
used for the reactions were as follows:S1P2 FWD CACTCGGCAATGTACCTGTTTC
RV GACGCCTAGCACGATGGTGAC
S1P3 FWD GACTGCTCTACCATCCTGCCC
RV GTAGATGACCGGGTTCATGGC
LPP1 FWD CTTCAAGGCATACCCCCTTCCAAC
REV GCCCAGTCTCCCTTCATCCTG
LPP2 FWD CTGCTGTATACAAGGTGCTGGGG
REV CGTGCCCACTTCCAACAGAGTC
LPP3 FWD CTCGACCTCTTCTGCCTCTTCATG
REV GCTTCCTGGACTTTGCTGTCATCAC
GAPDH FWD TGAAGGTCGGTGTCAACGGATTTGGC
RV CATGTAGGCCATGAGGTCCACCAC
The PCR reaction conditions were: 1 cycle initial denaturation at
94 °C for 2 min, 30 cycles ampliﬁcation at 94 °C for 1 min 30 s, 52 °C
(LPP1, LPP3, GAPDH) or 54 °C (LPP2) or 56 °C (S1P2 and S1P3 for 30 s
and 72 °C for 1 min 40 s, followed by a ﬁnal extension at 72 °C for
5 min.Fig. 1. Structures of FTY720, (S)-FTY720 vinylphosphonate, (R)-FTY720 vinylphosphona3. Results and discussion
3.1. FTY720 and (R and S)-FTY720 vinylphosphonate inhibit SK1 activity
Using sphingosine (10 μM) and [32P]ATP as substrates, we found
that 50 μM FTY720 (see Fig. 1) inhibited the activity of puriﬁed SK1 by
∼ 40% (Fig. 2a). The % inhibition by FTY720 was equivalent to that
observed with the same concentration of DMS or SKi, which are
established SK1 inhibitors [25–27] (Fig. 2a). Vessey and colleagues
also demonstrated that FTY720 inhibited SK1 activity in a chromato-
graphic fraction containing an anti-SK1 immunoreactive protein [28].
However, our ﬁndings are unequivocal in that they have been
obtained using puriﬁed SK1. Others have demonstrated that FTY720
is a substrate for SK2 [2–4] but not SK1, which we conﬁrmed using
FTY720 and [32P]ATP as substrates (data not shown). These ﬁndings
indicate that FTY720 binds to SK1, but is not phosphorylated. We also
tested a number of FTY720 analogues (see Fig. 1). We found that both
(S)-FTY720 vinylphosphonate and (R)-FTY720 vinylphosphonate
inhibited SK1 activity (Fig. 2a). The S enantiomer was signiﬁcantly
more effective than the R enantiomer at 50 μM. At this concentration,
(S)-FTY720 vinylphosphonate inhibited puriﬁed SK1 by more than
80%, whereas the R enantiomer inhibited the enzyme by 40% (Fig. 2a).
On a molar basis, (S)-FTY720 vinylphosphonate is much more
effective in inhibiting SK1 compared with FTY720, SKi or DMS
(Fig. 2a). Inhibition of SK1 activity by FTY720 analogues is reversible
(data not shown). The R and S enantiomers of FTY720 phosphonate
and (S)-FTY720 phosphate do not signiﬁcantly inhibit the enzyme
(Fig. 2a). (S)-FTY720 vinylphosphonate also inhibited SK1 activity
that had been ectopically over-expressed in HEK 293 cells and
this inhibition was concentration-dependent (Fig. 2b) with an IC50=
24±5.7 μM (n=3).
3.2. FTY720 and (S)-FTY720 vinylphosphonate induce proteasomal
degradation of SK1 in hPASMC and MCF-7 cells
Wehave demonstrated that DMS and SKi induce degradation of SK1
via the ubiquitin-proteasomal pathway to promote apoptosis of normal
and cancer cells unpublished. Therefore, since FTY720 and (S)-FTY720
vinylphosphonate are novel SK1 inhibitors, we explored the possibilityte, (S)-FTY720 phosphonate, (R)-FTY720 phosphonate and (S)-FTY720 phosphate.
Fig. 2. Assessment of FTY720 analogues on SK1 activity. (a) Effect of DMS, SKi and
various FTY720 analogues on puriﬁed SK1 activity (assayed using 10 μM sphingosine
and [32P]ATP (250 μM) as substrates). Results, expressed as percentage of vehicle
control are means and standard deviations of 3–4 independent experiments performed
in duplicate samples. All inhibitors were screened at 50 μM; (b) Concentration response
of the inhibitory effect of (S)-FTY720 vinylphosphonate on SK1 activity (using 10 μM
sphingosine and 250 μM [32P]ATP as the substrates) in lysates of HEK 293 cells in which
SK1 has been ectopically over-expressed.
Fig. 3. Effect of FTY720 and (S)-FTY720 vinylphosphonate on proteasomal degradation
of SK1a in hPASMC. Western blots showing the effect of: (a) FTY720 and (S)-FTY720
vinylphosphonate (both 10 μM, 24 h) on SK1a, ERK-2 and phosphorylated ERK-1/2
levels in hPASMC; (b) MG132 (10 μM, 24 h) on the FTY720- and (S)-FTY720
vinylphosphonate-induced down-regulation of SK1a; (c) FTY720 and (S)-FTY720
vinylphosphonate (both 10 μM, 24 h) on caspase-3 activation in hPASMC. C=control.
In each case, results are representative of 2–4 separate experiments.
Fig. 4. Effect of SKi, FTY720 and (S)-FTY720 vinylphosphonate on proteasomal
degradation of SK1a in MCF-7 cells. Western blot showing the effect of MG132
(10 μM, 24 h) on SKi-, FTY720- and (S)-FTY720 vinylphosphonate-induced degradation
of SK1a in MCF-7 cells. The cells were treated for 24 h with the inhibitors at 10 μM.
Results are representative of 3 separate experiments.
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SK1. Both hPASMC and MCF-7 cells express SK1a (Mr=42 kDa) (Figs.
3a, b and 4). Chronic treatment (24 h) of hPASMC (Fig. 3a, b) or MCF-7
breast cancer cells (Fig. 4) with FTY720 (10 μM) or (S)-FTY720
vinylphosphonate (10 μM) induced the down-regulation of SK1a.
Moreover, a 24-h treatment of hPASMC or MCF-7 cells with the
proteasomal inhibitorMG132 (10 μM) inhibited the down-regulation of
SK1a induced by either compound (Figs. 3b and 4). SKi (10 μM) was
used as a reference compound and was also shown to induce the
MG132-sensitive proteasomal degradation of SK1a in MCF-7 cells
(Fig. 4). It is well established that in order for proteins to be targeted for
proteasomal degradation, the protein must ﬁrst be modiﬁed by
ubiquitination. Therefore, our ﬁndings suggest that SK1a might be
regulated by the ubiquitin-proteasomal pathway and that the ﬂux of
SK1a through this pathway is increased by FTY720 and (S)-FTY720
vinylphosphonate. Indeed, Kihara and colleagues [29] reported that
SK1a and ‘SK1b’ (a smaller 34 kDa species) are regulated by the
ubiquitin-proteasomal degradation pathway with ‘SK1b’ being more
susceptible to polyubiquitination.Wedidnot detect the34 kDa ‘SK1b’ in
MCF-7 cells or hPASMC.
We next investigated the functional signiﬁcance of the FTY720-
and (S)-FTY720 vinylphosphonate-induced proteasomal degradation
of SK1 in terms of cellular response. In this regard, treatment of
hPASMC with either compound induced the onset of apoptosis asevidenced by increased caspase-3 activation (p17/p19 formation,
Fig. 3c). Moreover, FTY720 and (S)-FTY720 vinylphosphonate reduced
the phosphorylation state of ERK-1/2 in hPASMC (Fig. 3a), an enzyme
required for maintenance of cell survival. These ﬁndings demonstrate
that SK1a is critical for hPASMC survival.
3.3. FTY720 and (S)-FTY720 vinylphosphonate induce proteasomal
degradation of SK1 in LNCaP-AI prostate cancer cells
We also investigated whether the proteasomal degradation of SK1
induced by FTY720 and (S)-FTY720 vinylphosphonate is more
widespread and is evident in prostate cancer cells. LNCaP-AI cells
1540 F. Tonelli et al. / Cellular Signalling 22 (2010) 1536–1542express both SK1a (Mr=42 kDa) and SK1b (Mr=51 kDa) (Fig. 5a, b).
The treatment of LNCaP-AI cells with FTY720 or (S)-FTY720 vinylpho-
sphonate reduced SK1a expression via the MG132-sensitive protea-
somal degradation pathway (Fig. 5a). Similar results were also
obtained for SK1b, although (S)-FTY720 vinylphosphonate was
more effective than FTY720 in promoting the proteasomal degrada-
tion of SK1b (Fig. 5b). This can be correlated with the extent to which
these compounds inhibit puriﬁed SK1 catalytic activity (Fig. 2a). In
terms of the effect of these agents on apoptosis, we found that at
equimolar concentrations, (S)-FTY720 vinylphosphonate induced
PARP cleavage, while FTY720 was not effective (Fig. 6a). This might
suggest that there is a threshold level of SK1b, below which LNCaP-AI
cells are forced to undergo apoptosis. Thus, (S)-FTY720 vinylpho-
sphonate might reduce SK1b expression to below this threshold,
while FTY720 fails to do so.
Treatment of LNCaP-AI cells with 10 μM FTY720 or (S)-FTY720
vinylphosphonate also induced down-regulation of AR expression
(Fig. 6b). Moreover, a similar effect was observed in cells treated with
SKi (Fig. 6b), suggesting that this might be a common feature of SK1
inhibitors. The elimination of constitutively active AR by FTY720 and
(S)-FTY720 vinylphosphonate suggests that these compounds may be
effective inhibitors of the growth of androgen-independent prostate
cancer cells.
There are at least two possible models that describe the interaction
between FTY720/(S)-FTY720 vinylphosphonate and SK1 that results
in its proteasomal degradation. First, FTY720 or (S)-FTY720 vinylpho-
sphonate may bind to SK1, thereby inducing a conformational change
(leading to protein unfolding) that functions as a signal for its
ubiquitin-proteasomal degradation. Second, the binding of inhibitor
to SK1 induces a reduction in intracellular S1P formation and the
accumulation of sphingosine and ceramide (i.e. an increase in the
ceramide:S1P ratio). Ceramide, in turn, may activate the proteasome
to remove SK1 that is already polyubiquitinated. Indeed, our
preliminary results indicate that SK1 is polyubiquitinated under
basal conditions (data not shown), and a short-chain analogue of
ceramide, C2-ceramide has been shown to activate ubiquitin-
mediated proteolytic pathway in astrocytes [30]. The two models
described here are not necessarily mutually exclusive and may operate
together.
Our ﬁndings concerning SK1, extend the number of intracellular
targets of FTY720, which has been reported to also inhibit cytosolic
phospholipase A2 [31], S1P lyase [32] and ceramide synthase [33,34]
and to activate PP2A and PP2A-like phosphatases [35,36]. The effectsFig. 5. Effect of FTY720 and (S)-FTY720 vinylphosphonate on proteasomal degradation of SK1
on the FTY720- and (S)-FTY720 vinylphosphonate-induced degradation of (a) SK1a and (b
Western blots were reprobed with anti-actin antibody to ensure comparable protein loadinon these intracellular targets may explain the anti-cancer activity of
FTY720, of which there are numerous examples. For instance, FTY720
inhibits the invasive ability of androgen-independent prostate cancer
cells (DU145 and PC-3) via a mechanism that involves down-
regulation of RhoA-GTP [37]. FTY720, via functional antagonism of
S1P1 receptors, also reduces VEGF- and S1P-induced angiogenesis and
vascular permeability in vivo in growth factor implant and corneal
models [38]. FTY720 also reduces tumour metastasis in a mouse B16/
BL6 melanoma model, accompanied by a decrease in tumour cell
proliferation and an increase in apoptosis [38]. FTY720 also dramat-
ically decreases metastasis in a mouse model of breast cancer created
by inoculating JYgMC(A) cells into the ﬂank of BALB/c nu/nu mice
[39].
3.4. Molecular basis for overcoming chemotherapeutic resistance
The ability of (S)-FTY720 vinylphosphonate to induce proteasomal
degradation of SK1 and to promote apoptosis demonstrate that SK1 is
critical for cell survival. How is this achieved at the molecular level?
The most obvious candidate is S1P, which has both extracellular
actions at S1P receptors and intracellular actions at undeﬁned targets
[1]. Indeed, there is substantial evidence that S1P formed by SK1 is
released from cells or partitions into a lipidmicroenvironment in close
proximity to S1P receptors, whereupon binding to the S1P receptor(s)
induces ‘inside-out’ signalling [40] that, in this case, might protect
LNCaP-AI cell from apoptosis. Indeed, S1P2 and S1P3mRNA transcripts
are substantially increased in LNCaP-AI cells compared with LNCaP
cells (Fig. 7), suggesting that S1P formed by SK1 is accommodated for
by increased expression of S1P2/3 in LNCaP-AI cells. In addition, we
have investigated possible changes in the enzymes that regulate S1P
degradation termed lipid phosphate phosphatases (LPP1-3) [41].
These enzymes catalyse dephosphorylation of lysophospholipids such
as S1P, ceramide 1-phosphate and lysophosphatidic acid [41]. In this
regard, we demonstrate here that LPP2, but not LPP1 or LPP3 mRNA
transcript is markedly reduced in LNCaP-AI cells compared with
LNCaP cells (Fig. 8). These ﬁndings suggest that the bioavailability of
S1P at S1P2/3 receptors might be increased in LNCaP-AI cells.
Therefore, the ‘inside out’ signalling by S1P might be the critical
element in the acquisition of resistance to chemotherapeutic agents in
androgen-independent prostate cancer. Notably, this resistance can
be overcome by (S)-FTY720 vinylphosphonate. This might be a
consequence of reducing SK1a and SK1b levels to below a threshold.
Moreover, in the accompanying paper, Valentine and colleagues [42]a and SK1b in LNCaP-AI cells. Western blots showing the effect of MG132 (10 μM, 48 h)
) SK1b in LNCaP-AI cells. The cells were treated for 48 h with 10 μM of each inhibitor.
g. In each case, results are representative of 3 separate experiments.
Fig. 6. Effect of FTY720 and (S)-FTY720 vinylphosphonate on PARP cleavage and AR expression in LNCaP-AI cells. Western blots showing (a) the effect of FTY720 and (S)-FTY720
vinylphosphonate (both 10 μM, 48 h) on PARP cleavage in LNCaP-AI cells; (b) the effect of SKi (1 and 10 μM, 48 h), FTY720 (10 μM, 48 h) or (S)-FTY720 vinylphosphonate (10 μM,
48 h) on AR expression in LNCaP-AI cells. Western blots were re-probed with anti-actin antibody to ensure comparable protein loading. In each case, results are representative of 3
separate experiments.
1541F. Tonelli et al. / Cellular Signalling 22 (2010) 1536–1542have demonstrated that (S)-FTY720 vinylphosphonate is a pan S1P
receptor antagonist, and this activity might contribute to its apoptotic
action in LNCaP-AI cells by preventing ‘inside-out’ signalling by SK1.
Valentine and colleagues [42] have also demonstrated that low
nM concentrations of (S)-FTY720 vinylphosphonate elicits an anti-
apoptotic effect in IEC-6 intestinal epithelial cells challenged with
camptothecin (CPT). The concentration-response is bell shaped such
that the anti-apoptotic effect is lost at higher concentrations of (S)-
FTY720 vinylphosphonate. This bell shaped response is therefore
consistent with our observation that higher concentrations of (S)-
FTY720 vinylphosphonate promote apoptosis. CPT also induces an
increase in S1P receptor and SK1 expression in androgen-independent
prostate cancer cells and this has been proposed to underlie the
resistance to CPT-stimulated apoptosis in androgen-independent
prostate cancer cells [43]. If this is a generic mechanism, then the
increase in S1P receptor/SK1 expression with CPT might reduce
sensitivity of IEC-6 intestinal epithelial cells to (S)-FTY720 vinylpho-
sphonate in terms of the induction of apoptosis, thereby accounting for
the predominance of its anti-apoptotic action at lower concentrations.Fig. 7. Comparison of mRNA transcript levels of S1P2 and S1P3 in LNCaP and LNCaP-AI
cells. RT-PCR was conducted using S1P2 or S1P3 speciﬁc primers using 0.15 μg of RNA
isolated from either LNCaP or LNCaP-AI cells. An RT-PCR using GAPDH primers was
performed to conﬁrm that similar amounts of RNA were used between cell types. In
each case, results are representative of 3 separate experiments.3.5. Summary
Our ﬁndings demonstrate that (S)-FTY720 vinylphosphonate is a
more effective inhibitor of SK1 catalytic activity than DMS and SKi.
(S)-FTY720 vinylphosphonate also promotes the novel proteasomal
degradation of SK1 in hPASMC, MCF-7 and LNCaP-AI cells. The ability
of (S)-FTY720 vinylphosphonate to overcome the chemotherapeutic
resistance of LNCaP-AI prostate cancer cells suggests that this
compound may be a useful agent for treating androgen-independent
prostate cancer, for which there are currently limited therapeuticFig. 8. Comparison of mRNA transcript levels of LPP1-3 in LNCaP and LNCaP-AI cells. RT-
PCR was conducted using LPP1 or LPP2 or LPP3 speciﬁc primers using 0.15 μg of RNA
isolated from either LNCaP or LNCaP-AI cells. An RT-PCR using GAPDH primers was
performed to conﬁrm that similar amounts of RNA were used between cell types. In
each case, results are representative of 3 separate experiments.
1542 F. Tonelli et al. / Cellular Signalling 22 (2010) 1536–1542options. In this regard, combination therapies with γ-irradiation
might prove highly efﬁcacious as γ-irradiation-induced formation of
ceramide, which induces apoptosis [44], should theoretically be
potentiated by the (S)-FTY720 vinylphosphonate-induced proteaso-
mal degradation of SK1.
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